(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:152361

Synonyms

beta-D-galacto-hexopyranosyl-(1->2)-[beta-D-gluco-hexopyranosyl-(1->4)]-D-galacto-hexopyranose
Gal(b1-2)[Glc(b1-4)]Gal
WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2112h-1b_1-5][a2122h-1b_1-5]/1-2-3/a2-b1_a4-c1

Definition

References

GlyGen:G61550NK
GlyTouCan:G61550NK

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model